142 filings
10-Q
2024 Q1
AKLI
Akili Inc
Quarterly report
14 May 24
4:16pm
8-K
AKLI
Akili Inc
14 May 24
Akili Reports First Quarter 2024 Financial Results and Provides Business Update
4:10pm
8-K
AKLI
Akili Inc
30 Apr 24
Akili Announces Amended Agreement with Shionogi, Shift in Corporate Strategy and Release Date for First Quarter 2024 Financial Results
8:14am
8-K
AKLI
Akili Inc
23 Apr 24
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:25pm
ARS
2023 FY
AKLI
Akili Inc
6 Mar 24
Annual report to shareholders
4:28pm
DEFA14A
cmu e6yot
6 Mar 24
Additional proxy soliciting materials
4:11pm
S-8
h3ddvz84ta3woq
29 Feb 24
Registration of securities for employees
4:47pm
8-K
h8k95kl5b
29 Feb 24
Akili Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
12:00am
8-K
a3c qa03eb9i
26 Feb 24
Japanese Product Now Under Review for Nationwide Marketing Approval
9:04am
PRE 14A
pj5xwwh8jt8
23 Feb 24
Preliminary proxy
7:57am
8-K
sziihyob7aq
21 Feb 24
Akili Announces Release Date for Fourth Quarter and Full Year 2023
4:11pm
8-K
1ceupr9v
5 Jan 24
Departure of Directors or Certain Officers
4:17pm
8-K
ppu9ox0xpa1s3g4p4as
20 Dec 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:58pm
8-K
l19ced4708fw9ghoco3
18 Dec 23
EndeavorRx®, World’s First and Only Prescription Video Game Treatment, Secures FDA Label Expansion for Pediatric ADHD Patients Aged 13-17
8:10am
8-K
dk4wya
9 Nov 23
Akili Reports Third Quarter 2023 Financial Results and Provides Business Update
4:08pm
8-K
f3hgpi xzdwk14
27 Oct 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:20pm
8-K
tuvqtrqrn7 b2t8f0qn
6 Oct 23
Akili Announces Leadership Transition
7:07am